NewAmsterdam Pharma N.V.

10.46
-0.89 (-7.84%)
At close: Mar 28, 2025, 3:55 PM
11.04
5.57%
After-hours: Mar 28, 2025, 04:06 PM EDT

NewAmsterdam Pharma Income Statement

Year FY24 FY23 FY22 FY21 FY20
Revenue 45.56M 12.76M 95.91M n/a n/a
Cost of Revenue n/a n/a n/a n/a n/a
Gross Profit 45.56M 12.76M 95.91M n/a n/a
Operating Income -176.29M -165.73M -3.32M -30.73M -5.43M
Interest Income 16.88M 10.22M 268.03K 361.1K 344K
Pretax Income -241.6M -160.25M -21.14M -36.71M -5.75M
Net Income -241.6M -176.94M -21.14M -36.71M -5.75M
Selling & General & Admin 70.45M 29.77M 18.22M 5.27M 1.38M
Research & Development 151.41M 159.42M 81.01M 25.46M 4.04M
Other Expenses n/a n/a n/a n/a n/a
Operating Expenses 221.85M 197.06M 116.78M 36.35M 5.4M
Interest Expense n/a 6.8M n/a n/a n/a
Selling & Marketing Expenses n/a 4.06M 1.6M 858.39K 11K
Cost & Expenses 221.85M 183.23M 116.78M 36.35M 5.4M
Income Tax -1K 27K n/a n/a n/a
Shares Outstanding (Basic) 94.36M 82.16M 18.97M 17.75M 17.75M
Shares Outstanding (Diluted) 94.36M 82.16M 18.97M 17.75M 17.75M
EPS (Basic) -2.56 -2.15 -1.11 -3.34 -1.15
EPS (Diluted) -2.56 -2.15 -1.11 -3.34 -1.15
EBITDA -241.49M -176.86M -3.31M -30.73M -5.43M
Depreciation & Amortization -65.2M 49K 8.4K 4.39K 1K